filings.toolsItem 16. FORM 10-K SUMMARY
4K characters. Original on sec.gov ·
Item 16. FORM 10-K SUMMARY
None.
| Pfizer Inc. | 2020 Form 10-K | 116 |
SIGNATURES
Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.
| Pfizer Inc. | |||||||||||
| Dated: February 25, 2021 | By: | /S/ MARGARET M. MADDEN | |||||||||
| Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel |
We, the undersigned directors and officers of Pfizer Inc., hereby severally constitute Douglas M. Lankler and Margaret M. Madden, and each of them singly, our true and lawful attorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Under the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacities and on the date indicated.
| Signature | Title | Date | ||||||||||||
| /S/ ALBERT BOURLA Albert Bourla | Chairman and Chief Executive Officer (Principal Executive Officer) | February 23, 2021 | ||||||||||||
| /S/ FRANK A. D’AMELIO Frank A. D’Amelio | Chief Financial Officer and Executive Vice President, Global Supply (Principal Financial Officer) | February 23, 2021 | ||||||||||||
| /S/ JENNIFER B. DAMICO Jennifer B. Damico | Senior Vice President and Controller (Principal Accounting Officer) | February 24, 2021 | ||||||||||||
| /S/ RONALD E. BLAYLOCK Ronald E. Blaylock | Director | February 24, 2021 | ||||||||||||
| /S/ SUSAN DESMOND-HELLMANN Susan Desmond-Hellmann | Director | February 23, 2021 | ||||||||||||
| /S/ JOSEPH J. ECHEVARRIA Joseph J. Echevarria | Director | February 23, 2021 | ||||||||||||
| /S/ SCOTT GOTTLIEB Scott Gottlieb | Director | February 23, 2021 | ||||||||||||
| /S/ HELEN H. HOBBS Helen H. Hobbs | Director | February 23, 2021 | ||||||||||||
| /S/ SUSAN HOCKFIELD Susan Hockfield | Director | February 23, 2021 | ||||||||||||
| /S/ DAN R. LITTMAN Dan R. Littman | Director | February 23, 2021 | ||||||||||||
| /S/ SHANTANU NARAYEN Shantanu Narayen | Director | February 23, 2021 | ||||||||||||
| /S/ SUZANNE NORA JOHNSON Suzanne Nora Johnson | Director | February 23, 2021 | ||||||||||||
| /S/ JAMES QUINCEY James Quincey | Director | February 23, 2021 | ||||||||||||
| /S/ JAMES C. SMITH James C. Smith | Director | February 23, 2021 |
| Pfizer Inc. | 2020 Form 10-K | 117 |
Previous: Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES